Clinical Trial Update: Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a third and fourth dose of StaphVAX in adults with end-stage renal disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Staphylococcal Infections

Drugs mentioned

• StaphVAX

Snippet

Sponsor: Nabi Biopharmaceuticals | Conditions: Staphylococcal Infections, Chronic Kidney Failure | Phase 3 | Status: TERMINATED